Heart failure is a global pandemic affecting an estimated 26 million people worldwide and
resulting in more than 1 million hospitalizations annually in both the United States and …

With a prevalence of 5.8 million in the United States alone, heart failure (HF) is associated
with high morbidity, mortality, and healthcare expenditures. Close to 1 million …

Despite available therapy, mortality and readmission rates within 60–90 days of discharge
for patients hospitalized with heart failure (HF) approach 15% and 30%, respectively. This …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

PUBLISHED BY ELSEVIER levels stratified by age and sex. Estimates of several summary
epidemiological measures are produced, including composite measures such as …

RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone
system blockers on angiotensin-converting enzyme 2 levels and activity in humans are …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …